Fast-Acting Migraine Treatment Highlighted During National Migraine Awareness Month
SAN DIEGO,
June 6, 2011 /PRNewswire/ -- Thirty-six million Americans
suffer from migraines, leading to more than
$20 billion in medical expenses and costs related to lost productivity each year(1). In recognition of National Migraine Awareness Month and the significant unmet medical needs of migraine patients, Zogenix, Inc. (NASDAQ: ZGNX) is highlighting the importance of selecting the appropriate medication for a patient's "treatment toolbox" to address specific types of migraine episodes.
To view the multimedia assets associated with this release, please click: http://multivu.prnewswire.com/mnr/zogenix/50344/
This multi-therapy treatment strategy is endorsed by headache specialists and is supported by the results of a Phase 4 clinical study of the Company's fast-acting needle-free subcutaneous migraine treatment, SUMAVEL DosePro, which were presented at the annual meeting of the American Headache Society in Washington, D.C. The study demonstrated increased patient satisfaction, confidence and preference for SUMAVEL DosePro in the treatment of migraine attacks.
Roger K. Cady, MD, associate executive chairman of the National Headache Foundation board of directors and founder of the Headache Care Center in Springfield, MO, said, "Migraines are a serious medical condition that can severely impair a patient's ability to function in day-to-day activities. They are difficult to treat because there is a broad spectrum of migraines with significant variability in intensity, nausea, associated vomiting and speed of onset. Clinical experience suggests that the key to winning the battle is a multi-therapy approach that includes a fast-acting, convenient and easy-to use option for the more aggressive migraine attacks."
Oral triptans are a commonly prescribed class of migraine medications, however, more than 50% of migraine sufferers using oral medications have indicated they are dissatisfied with their current migraine therapy(2).Select the service that is right for you!
COMPARE ALL SERVICESAction Alerts PLUS
TRY IT FREEJim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
Product Features:
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Dividend Stock Advisor
TRY IT FREENew! $49.95/yr
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Product Features:
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Stocks Under $10
TRY IT FREEDavid Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.
Product Features:
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
- Weekly roundups
Real Money
TRY IT FREE24/7 market commentary from Jim Cramer and 20+ veteran Wall Street gurus. Get access to the latest trading ideas on stocks, options, and ETFs as well as a real-time forum to see the pros exchanging their investment ideas.
Product Features:
- Jim Cramer + 20 Wall Street pros
- Intraday commentary & news
- Real-time trading forum
- Actionable trade ideas
Real Money Pro
TRY IT FREEAll of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
Product Features:
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Options Profits
TRY IT FREEOur options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
Product Features:
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
